Literature DB >> 15177455

Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acid.

Webster L Santos1, Brian H Heasley, Renata Jarosz, Karen M Carter, Kevin R Lynch, Timothy L Macdonald.   

Abstract

Using an N-oleoyl ethanolamide scaffold, a series of phosphate polar head group analogues of LPA comprised of various alpha-substituted phosphonates and thiophosphates was prepared. In a broken cell GTP[gamma35S] binding assay, agonist activity was evaluated at the three LPA receptors of the endothelial differentiation gene (Edg) family. This study has resulted in the discovery of a nonhydrolyzable LPA1-selective agonist (11). Additionally, thiophosphate 19 bears an isosteric phosphate mimetic that confers agonism at the LPA1 receptor but not LPA2.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15177455     DOI: 10.1016/j.bmcl.2004.04.061

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  9 in total

Review 1.  Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.

Authors:  Dong-Soon Im
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

2.  Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.

Authors:  Peng Cui; Jose L Tomsig; William F McCalmont; Sangderk Lee; Christopher J Becker; Kevin R Lynch; Timothy L Macdonald
Journal:  Bioorg Med Chem Lett       Date:  2007-01-13       Impact factor: 2.823

3.  Identification of non-lipid LPA3 antagonists by virtual screening.

Authors:  James I Fells; Ryoko Tsukahara; Yuko Fujiwara; Jianxiong Liu; Donna H Perygin; Daniel A Osborne; Gabor Tigyi; Abby L Parrill
Journal:  Bioorg Med Chem       Date:  2008-04-18       Impact factor: 3.641

4.  Development of a phosphatase-resistant, L-tyrosine derived LPA1/LPA3 dual antagonist.

Authors:  James E East; Karen M Carter; Perry C Kennedy; Nancy A Schulte; Myron L Toews; Kevin R Lynch; Timothy L Macdonald
Journal:  Medchemcomm       Date:  2011-03-03       Impact factor: 3.597

5.  Lysophosphatidic acid receptor agonists and antagonists (WO2010051053).

Authors:  Abby L Parrill
Journal:  Expert Opin Ther Pat       Date:  2011-01-11       Impact factor: 6.674

6.  Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX).

Authors:  James E East; Andrew J Kennedy; Jose L Tomsig; Alexandra R De Leon; Kevin R Lynch; Timothy L Macdonald
Journal:  Bioorg Med Chem Lett       Date:  2010-09-15       Impact factor: 2.823

Review 7.  Lysophospholipid interactions with protein targets.

Authors:  Abby L Parrill
Journal:  Biochim Biophys Acta       Date:  2008-05-02

8.  Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA.

Authors:  Guowei Jiang; Yong Xu; Yuko Fujiwara; Tamotsu Tsukahara; Ryoko Tsukahara; Joanna Gajewiak; Gabor Tigyi; Glenn D Prestwich
Journal:  ChemMedChem       Date:  2007-05       Impact factor: 3.466

9.  A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), UCM-05194, Shows Efficacy in Neuropathic Pain Amelioration.

Authors:  Inés González-Gil; Debora Zian; Henar Vázquez-Villa; Gloria Hernández-Torres; R Fernando Martínez; Nora Khiar-Fernández; Richard Rivera; Yasuyuki Kihara; Isabel Devesa; Sakthikumar Mathivanan; Cristina Rosell Del Valle; Emma Zambrana-Infantes; María Puigdomenech; Giovanni Cincilla; Melchor Sanchez-Martinez; Fernando Rodríguez de Fonseca; Antonio V Ferrer-Montiel; Jerold Chun; Rubén López-Vales; María L López-Rodríguez; Silvia Ortega-Gutiérrez
Journal:  J Med Chem       Date:  2019-12-16       Impact factor: 7.446

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.